KR20130027579A - 세포 배양으로부터 수명 및 단백질 수율을 증가시키기 위한 개선된 방법 및 조성물 - Google Patents

세포 배양으로부터 수명 및 단백질 수율을 증가시키기 위한 개선된 방법 및 조성물 Download PDF

Info

Publication number
KR20130027579A
KR20130027579A KR1020137004422A KR20137004422A KR20130027579A KR 20130027579 A KR20130027579 A KR 20130027579A KR 1020137004422 A KR1020137004422 A KR 1020137004422A KR 20137004422 A KR20137004422 A KR 20137004422A KR 20130027579 A KR20130027579 A KR 20130027579A
Authority
KR
South Korea
Prior art keywords
cells
cell line
antibody
bcl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137004422A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 엠 골든버그
젱칭 쿠
시엔 싱 창
에드워드 에이 로시
젱-다 양
다이안 노르드스트롬
Original Assignee
이뮤노메딕스, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노메딕스, 인코오포레이티드 filed Critical 이뮤노메딕스, 인코오포레이티드
Publication of KR20130027579A publication Critical patent/KR20130027579A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020137004422A 2005-07-25 2006-07-14 세포 배양으로부터 수명 및 단백질 수율을 증가시키기 위한 개선된 방법 및 조성물 Ceased KR20130027579A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/187,863 US7531327B2 (en) 2004-07-23 2005-07-25 Methods and compositions for increasing longevity and protein yield from a cell culture
US11/187,863 2005-07-25
PCT/US2006/027820 WO2007015848A2 (en) 2005-07-25 2006-07-14 Improved methods and compositions for increasing longevity and protein yield from a cell culture

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087002132A Division KR101518062B1 (ko) 2005-07-25 2006-07-14 세포 배양으로부터 수명 및 단백질 수율을 증가시키기 위한개선된 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20130027579A true KR20130027579A (ko) 2013-03-15

Family

ID=37709058

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137004422A Ceased KR20130027579A (ko) 2005-07-25 2006-07-14 세포 배양으로부터 수명 및 단백질 수율을 증가시키기 위한 개선된 방법 및 조성물
KR1020087002132A Active KR101518062B1 (ko) 2005-07-25 2006-07-14 세포 배양으로부터 수명 및 단백질 수율을 증가시키기 위한개선된 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087002132A Active KR101518062B1 (ko) 2005-07-25 2006-07-14 세포 배양으로부터 수명 및 단백질 수율을 증가시키기 위한개선된 방법 및 조성물

Country Status (8)

Country Link
US (1) US7531327B2 (enExample)
EP (1) EP1910515B1 (enExample)
JP (2) JP5301990B2 (enExample)
KR (2) KR20130027579A (enExample)
CN (1) CN101273121B (enExample)
AU (1) AU2006276182B2 (enExample)
CA (1) CA2616799C (enExample)
WO (1) WO2007015848A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) * 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US20070092947A1 (en) * 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
KR101802393B1 (ko) * 2008-06-10 2017-11-28 상가모 테라퓨틱스, 인코포레이티드 Ｂａｘ- 및 ｂａｋ-결함 세포주들의 제조 방법 및 조성물
ES2557903T3 (es) * 2008-06-13 2016-01-29 Janssen Biotech, Inc. Métodos para obtener una alta densidad celular viable en cultivos celulares de mamíferos
DE102008051574A1 (de) * 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
CN102369276B (zh) 2009-02-20 2015-02-04 文特里亚生物科学公司 含有蛋白质组合的细胞培养基
CN101899471B (zh) * 2009-05-26 2014-06-11 中国医学科学院基础医学研究所 同时表达抗原特异性受体和外源基因的重组逆转录病毒载体、用其修饰的b-淋巴细胞及其用途
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
US20120028933A1 (en) 2010-07-28 2012-02-02 Baust John M Cell Culture Media Supplement and Method of Molecular Stress Control
JP5665065B2 (ja) 2011-04-28 2015-02-04 国立大学法人大阪大学 リソソーム病治療用医薬組成物
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
CN105378071B (zh) * 2013-03-15 2021-04-20 美克斯细胞有限公司 用于产生稳定转染细胞的方法和组合物
EA201991976A1 (ru) * 2013-10-11 2020-04-02 Регенерон Фармасьютикалз, Инк. Метаболически оптимизированная клеточная культура
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
JP6678941B2 (ja) 2014-10-07 2020-04-15 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 抗体−薬物コンジュゲートのネオアジュバント使用
CA2982759C (en) 2015-04-13 2025-05-20 Maxcyte, Inc. PROCESSES AND COMPOSITIONS THAT ALLOW FOR MODIFICATION OF GENOMIC DNA
JP6746845B2 (ja) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
US10745663B2 (en) * 2015-07-17 2020-08-18 Ares Trading S.A. Methods for modulating production profiles of recombinant proteins
TWI784063B (zh) * 2017-12-27 2022-11-21 財團法人生物技術開發中心 具有增進蛋白質表現功效的宿主細胞及其用途
KR20210030949A (ko) * 2018-07-13 2021-03-18 론자 리미티드 내인성 단백질의 수준을 감소시켜 생물학적 생성물의 생산을 개선하는 방법
CN111349615B (zh) * 2018-12-24 2024-08-13 上海细胞治疗集团股份有限公司 制备过表达外源基因的细胞的方法
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen
KR20230078937A (ko) * 2021-11-26 2023-06-05 한양대학교 산학협력단 유전자 과발현을 이용해 조건부 성숙이 가능한 적혈구 전구세포주 확립

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0471484A (ja) * 1990-07-11 1992-03-06 Teijin Ltd 低凝集性細胞及びその培養方法
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DK1650307T3 (da) * 1999-09-27 2010-10-04 Genentech Inc Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer
AU2001294520A1 (en) 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
MXPA04000281A (es) 2001-07-10 2004-07-23 Idec Pharma Corp Inhibicion del proceso de apoptosis y mejora del rendimiento celular.
WO2003040374A1 (en) 2001-11-02 2003-05-15 Centocor, Inc. METHODS AND COMPOSITIONS FOR ENHANCED PROTEIN EXPRESSION AND/OR GROWTH OF CULTURED CELLS USING CO-TRANSCRIPTION OF A Bcl2 ENCODING NUCLEIC ACID
US6964199B2 (en) 2001-11-02 2005-11-15 Cantocor, Inc. Methods and compositions for enhanced protein expression and/or growth of cultured cells using co-transcription of a Bcl2 encoding nucleic acid
WO2003052064A2 (en) * 2001-12-14 2003-06-26 Centocor Inc. Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
EP1348758A1 (en) 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Host cells having improved cell survival properties and methods to generate such cells
US20030219871A1 (en) 2002-03-28 2003-11-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Host cells having improved cell survival properties and methods to generate such cells
EP1563073A4 (en) * 2002-06-26 2007-09-19 Biogen Idec Inc PROTEIN PRODUCTION METHODS AND MODIFIED CELLS FOR USE IN SUCH METHODS
AU2004280064A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell neutralized to serum-free system
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
CN1287862C (zh) * 2004-09-29 2006-12-06 中国人民解放军第四军医大学 MG7－Ag模拟表位构建胃癌特异性多表位基因疫苗的方法
US20070092947A1 (en) 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture

Also Published As

Publication number Publication date
KR20080073282A (ko) 2008-08-08
US20060110793A1 (en) 2006-05-25
WO2007015848A2 (en) 2007-02-08
CA2616799A1 (en) 2007-02-08
EP1910515B1 (en) 2019-02-27
AU2006276182A1 (en) 2007-02-08
AU2006276182B2 (en) 2012-02-16
JP5301990B2 (ja) 2013-09-25
CN101273121B (zh) 2012-07-04
WO2007015848A9 (en) 2007-04-05
WO2007015848A3 (en) 2007-10-04
EP1910515A2 (en) 2008-04-16
CA2616799C (en) 2015-11-24
WO2007015848B1 (en) 2007-11-15
JP2009502167A (ja) 2009-01-29
KR101518062B1 (ko) 2015-05-28
JP2013172722A (ja) 2013-09-05
EP1910515A4 (en) 2009-03-11
CN101273121A (zh) 2008-09-24
US7531327B2 (en) 2009-05-12

Similar Documents

Publication Publication Date Title
KR101518062B1 (ko) 세포 배양으로부터 수명 및 단백질 수율을 증가시키기 위한개선된 방법 및 조성물
US8153433B1 (en) Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7608425B2 (en) Methods for protein expression in mammalian cells in serum-free medium
WO2009080816A1 (en) Fusion polypeptides comprising a shbg dimerization component and uses thereof
EP1802646B1 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
US20070092947A1 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
CN114196702A (zh) 一种利用单碱基编辑器构建长qt疾病干细胞的方法
CN114457118B (zh) 一种荧光报告基因元件、基因编辑监测系统及其用途
CN114574479B (zh) 一种高通量组装嵌合抗原受体的方法及其应用
KR102265924B1 (ko) Pdk 불활성화에 의한 폴리펩타이드의 생산
RU2834407C1 (ru) Способ конструирования и применение вектора дисплея генов антигенспецифических связывающих полипептидов
KR102287725B1 (ko) 지방산 결합 단백질 과발현에 의한 재조합 폴리펩타이드의 생산
KR20160085666A (ko) Got1 과발현에 의한 재조합 폴리펩타이드의 생산
CN116536353A (zh) 一种复制型高效引导编辑系统
AU2005333513A1 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
KR20160085664A (ko) Mpc1 과발현에 의한 재조합 폴리펩타이드의 생산 증대

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130221

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130402

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130402

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I